Sana biotechnology highlights preclinical hypoimmune data for its allogeneic car t platform and advancements with its in vivo fusogen platform with four presentations at the 2023 aacr annual meeting

Hypoimmune-modified cd19-directed car t cells persist and remain functional in preclinical models over multiple months in an allogeneic humanized immune system, even with tumor re-challenge

SANA Ratings Summary

SANA Quant Ranking